Prime Medicine, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Prime Medicine, Inc. (PRME) develops gene editing therapies using its proprietary Prime Editing platform, a next-generation technology that enables precise search-and-replace DNA modifications without double-strand breaks to treat genetic diseases across hematology, immunology and oncology, liver, and lung therapeutic areas. The company offers a pipeline of investigational programs including PM359, an ex vivo autologous hematopoietic stem cell therapy delivered via electroporation for p47phox chronic granulomatous disease (CGD) currently in Phase 1/2 trials under the Prime-0101 study and holding rare pediatric and orphan drug designations from the U.S. FDA; in vivo lipid nanoparticle (LNP)-delivered Prime Editors for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD), with PM647 nominated as the AATD development candidate in August 2025; LNP/AAV Prime Editors incorporating PASSIGE technology for cystic fibrosis; and ex vivo CAR-T cell products incorporating PASSIGE for immunology and oncology indications. Prime Medicine operates primarily in the United States, targeting patients with debilitating genetic disorders through one-time curative therapies. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company recently entered a strategic license and broad collaboration agreement with Bristol Myers Squibb in September 2024 to develop and commercialize ex vivo T-cell Prime Editor products with up to $3.5 billion in potential value; secured up to $15 million from the Cystic Fibrosis Foundation in January 2024 to advance cystic fibrosis programs; appointed Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer in November 2025 to bolster strategic partnerships; narrowed its pipeline from 18 to four core preclinical and clinical programs focused on high-value liver and lung diseases; and completed a financing round extending its cash runway while presenting new preclinical data for Wilson's Disease PM577 at the AASLD meeting in late 2025.
Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Prime Medicine's Prime Editing Is Worth The Risk
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)
Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)